Does Zoloft Affect Sex Drive? What the Sertraline Trials Actually Show

You are asking two questions about zoloft and sex drive, and they deserve separate answers. The first is "is it the Zoloft, or is it me?" The second is "will it come back?" On the first: sertraline sits at the top of the 2009 meta-analysis ranking of ten antidepressants for treatment-emergent sexual dysfunction, and in the 1,022-person Spanish study, 62.9% of the people on sertraline reported a sexual problem when asked directly. On the second: the depression or the anxiety carries part of the drop, nobody can say for one person, and the side effect does not fade with time or dose. The add-ons with a trial signal are bupropion and, for men, the erection drugs.

Figures from Montejo et al. 2001 (PMID 11229449) and Khazaie et al. 2015 (PMID 25467077).

Is it the Zoloft, or is it me?

The internet merges these two questions into one, and the merged version misleads. If your drive dropped after starting sertraline, the drug is a live suspect, but the condition you took it for is one too. Depression and anxiety both drag down desire on their own, so some of what you are feeling may be the illness talking, with the drug adding its own layer on top. Nobody can sort that split for one person, and no test exists for it. What the data can do is show how often the drug does this, and how often it does not.

On frequency, Clayton and colleagues (2002) surveyed 4,534 women and 1,763 men on antidepressant monotherapy across 1,101 U.S. clinics. In a subpopulation unlikely to have predisposing factors, prevalence ran from 7% to 30%, and the odds were 4 to 6 times greater with SSRIs such as sertraline than with bupropion sustained release. The same survey found physicians consistently underestimated how often this happens. That study was cross-sectional, with no placebo comparator, and it reports per-drug rates only in banded form, so sertraline's own number is not printed there.

Brawman-Mintzer and colleagues (2006) ran a randomized double-blind placebo-controlled trial in generalized anxiety disorder: 326 adults on flexible-dose sertraline (50 to 200 milligrams per day) for 10 weeks. Sexual side effects were the only effect reported significantly more often with sertraline than with placebo. The between-group differences were small, which matters if you are weighing the trade-off before you start.

Katz and colleagues (2012) looked at the STAR*D trial, where 727 adults who had not responded to first-step citalopram switched to a second step. Distressing adverse events hit 70.7% on the first step and 86.1% on the second. People who reported a sexual-functioning event on the first step were 2.75 times more likely to report one on the second (95% CI 2.29 to 3.29). This was a secondary analysis, and the first step was fixed to citalopram, so it points at a pattern across SSRIs and says nothing specific about sertraline.

If you are taking sertraline for PMDD, the 2024 Cochrane review covers PMDD, a different population from depression. Across 14 studies and 1,742 participants, a sexual side effect carried an odds ratio of 2.32 (95% CI 1.57 to 3.42). For the wider picture, see our guide to SSRIs and the libido drop, depression and low libido, stress killing your sex drive, and, for the PMDD reader, sex drive and your menstrual cycle.

How often sertraline does this, by the numbers

Serretti and colleagues (2009) ran a meta-analysis of treatment-emergent sexual dysfunction, using direct inquiry in people without previous dysfunction. Ten antidepressants ranked significantly above placebo, in decreasing order of impact: sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, and fluvoxamine. Dysfunction across those ten drugs ranged from 25.8% to 80.3%. Read that range carefully: it spans all ten drugs, so it is not sertraline's own figure. Six others showed no significant difference from placebo: agomelatine, amineptine, bupropion, moclobemide, mirtazapine, and nefazodone. The authors flag two caveats that temper the ranking: open-label studies were included, and the studies used different scales.

Montejo and colleagues (2001) give the most concrete number. Their prospective multicenter open-label study in Spain followed 1,022 adults, 610 women and 412 men with a mean age of 39.8, who had previously normal sexual function and took antidepressants alone or with benzodiazepines. A questionnaire covered libido, finishing-phase items, erection scores, and satisfaction. Overall incidence was 59.1% (604 of 1,022). Men ran 62.4% versus women at 56.9%, with women higher in severity, and about 40% had low tolerance. The SSRIs and venlafaxine ran 58% to 73%, against lower rates for the 5-HT2 blockers (nefazodone, mirtazapine), moclobemide, and amineptine. Because the study was open-label and asked directly, treat these figures as the high end.

Kearns and colleagues (2022) built a systematic review, network meta-analysis, and economic model around placebo-controlled trials. All eight drugs they examined, sertraline among them, were associated with increased rates of a sexual side effect versus placebo. That is a model built from trial data, so it describes the trial populations and never you.

Chan and colleagues (2025) analyzed over 342,000 spontaneous safety reports across six SSRIs in the WHO database. Paroxetine carried the highest rate of a sexual side effect in that disproportionality analysis; sertraline did not. Disproportionality values reflect reporting patterns. They tell you what gets reported, and nothing about how often it happens at a given dose.

Sertraline against the other antidepressants

Montejo and colleagues (2001) let you line the drugs up. In that 1,022-person study, the per-drug rates for reporting a sexual problem were: citalopram 72.7% (48 of 66), paroxetine 70.7% (147 of 208), venlafaxine 67.3% (37 of 55), sertraline 62.9% (100 of 159), fluvoxamine 62.3% (48 of 77), fluoxetine 57.7% (161 of 279), mirtazapine 24.4% (12 of 49), nefazodone 8% (4 of 50), amineptine 6.9% (2 of 29), and moclobemide 3.9% (1 of 26). Sertraline sits in the high pack, behind three drugs and ahead of the rest. The study was open-label and relied on direct questioning, so every bar here leans high.

Reichenpfader and colleagues (2014) pooled 63 studies, more than 26,000 people, in a systematic review with Bayesian network meta-analysis of second-generation antidepressants in major depressive disorder. Most pairwise comparisons showed a similar risk among the drugs, with credible intervals wide enough to include clinically relevant differences. Bupropion came out significantly lower risk than some drugs; paroxetine and escitalopram significantly higher. The overall strength of evidence was rated low, with inconsistent reporting in some trials, selected populations, English-only inclusion, and indirect comparisons.

Kroenke and colleagues (2001) ran a randomized open-label trial across 37 U.S. clinics: 573 depressed adults on paroxetine, fluoxetine, or sertraline for 9 months. Responses were comparable on all measures at every time point, and quality of life in sexual functioning was among the domains tracked. The report prints no specific sexual-functioning numbers, and the design was open-label, so this tells you the drugs tracked together on the broad measures, little more.

Why it does not fade with time

This is the question behind "I just want to feel normal again," and the honest answer is that waiting has not been the fix. Landen and colleagues (2005) followed 119 people with a major depressive episode who had not responded to citalopram or paroxetine, asking about sexual function openly and directly at baseline and after four weeks of SSRI plus buspirone or placebo. Asked directly, 41% reported a problem; left to their own words, only 6% did. The problem correlated with the duration of the depressive episode, and with nothing else: age, dose, plasma level, time on the drug and every depression score all failed to predict it. The authors read that lack of correlation with time on the drug as a sign that SSRI sexual side effects do not abate over time. The sample was small and drawn from non-responders, so treat the direction as suggestive.

Jacobsen and colleagues (2015) put the point plainly in their report: the side effect does not resolve in most people. Their trial compared vortioxetine with escitalopram in adults whose depression was well treated but who had developed the side effect on citalopram, paroxetine, or sertraline. Both arms were an SSRI, with flexible dosing, so the comparison is between two drugs. Neither arm was drug-free.

Back at STAR*D, Katz and colleagues (2012) saw distressing adverse events climb from 70.7% on the first step to 86.1% on the second, and people who had reported a sexual-functioning problem initially were 2.75 times more likely to report one again. A secondary analysis, with the first step fixed to citalopram. If your numbers are fine and you still feel flat, numbers fine, still flat covers that territory.

What the switch and add-on trials found

Taylor and colleagues (2013) reviewed strategies for managing antidepressant-induced sexual dysfunction: 23 trials, 1,886 people. In men, sildenafil (three studies, 255 people) and tadalafil (one study, 54 people) led to greater improvement in erections than placebo. Bupropion 150 milligrams twice daily showed benefit on scale scores (SMD 1.60, 95% CI 1.40 to 1.81); once daily, it made no significant difference in response rates. The other augmentation strategies failed to show one. One trial, in 75 people with sertraline-induced problems, found switching to nefazodone significantly less likely to bring the dysfunction back than restarting sertraline (RR 0.34, 95% CI 0.19 to 0.60); nefazodone is no longer available. There are no randomized trials of switching to currently available lower-side-effect drugs, of psychological interventions, or of drug holidays.

For women, de Aquino and colleagues (2025) pooled pharmacological treatments: 11 studies, 859 women aged 28 to 48. Bupropion SR 150 milligrams twice daily improved desire and finishing-phase items versus placebo, and did not improve the depression itself. Only two of the eleven studies were pooled, and the GRADE rating was low, so the signal is real but thin.

Luft and colleagues (2021) widened the net: 33 interventions, 3,108 people. Forty-four percent of trials reported a successful intervention, and the split by design is stark: 70% of open-label trials versus 22% of placebo-controlled ones. Sildenafil carried the most consistent signal, and heterogeneity was high, so the open-label results should be read with care.

On switching between SSRIs, Jacobsen and colleagues (2015) found vortioxetine gave greater improvement on the CSFQ-14 total score than escitalopram (8.8 versus 6.6, P = 0.013, in 225 versus 222 people), with benefit on four of five dimensions. The 2020 subgroup analysis added that women (P = 0.045) and prior SSRI treatment (P = 0.044) favored vortioxetine. Both arms were an SSRI, with flexible dosing, so this is a within-class comparison. See what the bupropion trials show, what the escitalopram trials show, and libido after stopping antidepressants.

Two questions, two piles of evidence

You are standing between two different questions, and each one has its own pile of studies behind it. The first is about the drug: how often does sertraline (Zoloft) lower desire, and how does it rank against the other antidepressants? The second is about you: what can be done about a drop that has already happened, and will it come back on its own? The sources do not mix these up. One set ranks drugs by how many people report a change when asked directly. Another set tests add-ons and switches after the fact. Each pile can answer its own question well and the other poorly, so we keep them separate below, with the caveats that go with each one.

Add-on strategies for a sertraline (Zoloft) libido drop: what the evidence says, drug by drug.

Strategy	Best evidence	Result	Grade
Bupropion 150 milligrams twice daily	Cochrane, three studies, men and women	SMD 1.60, 95% CI 1.40 to 1.81	Limited but the strongest
Bupropion 150 milligrams once daily	Cochrane, two studies	RR 0.62, 95% CI 0.09 to 4.41	No signal at that dose
Sildenafil, men	Cochrane, three studies, 255 men	Better erection scores	Men only
Tadalafil, men	Cochrane, one study, 54 men	Better erection scores	Single study
Sildenafil, women	Cochrane; 2021 review	Uncertain; more responses, without significance	Uncertain
Switching antidepressants	No randomized trial of current lower-side-effect drugs	Untested	Untested
Switching to nefazodone	Cochrane, one trial, 75 people	RR 0.34, 95% CI 0.19 to 0.60	No longer available
Other add-ons	Cochrane	Failed to show significant improvement	Untested or null

What to bring to your prescriber

The drop is real, and the fix starts with a conversation. Bring this list, in this order, and let your prescriber work through it with you.

1. Which question you are asking. Is it the drug, or is it the illness? And do you want it to fade on its own, or do you want something added? The two have different answers.
2. The timeline. When you started, every dose change since, and that nothing has changed so far. This matters because the side effect does not track with dose or time.
3. Ask to be asked directly. In one small study, 41% of people reported the sexual side effect when asked straight out, against 6% who mentioned it on their own. If nobody asks, you may never say it.
4. Staying on it. While you remain on an SSRI, the side effect does not resolve in most people, and neither dose nor time on the drug predicts it. So waiting is not a plan with a number behind it.
5. The alternatives with a signal. Bupropion 150 milligrams twice daily, and for men the erection drugs, are the ones with a trial result. There is no randomized trial of switching, of psychological interventions, or of drug holidays.
6. The supplement question, bottle in hand. NUUD does nothing for depression, anxiety, PMDD, or medication side effects, and there are no interaction studies for this formula. Bring the label and ask.

"I've tried everything"

If you have been through the add-ons and came away empty-handed, here is the honest count, because the internet tends to round it up. The strategies that showed a signal in a trial are short. Bupropion 150 milligrams twice daily did. For men, the erection drugs did. Everything else in the Cochrane review failed to show a significant improvement, and that includes the once-daily bupropion dose, which carried no signal at that strength. A later review of 33 interventions across 3,108 people pointed the same way: sildenafil was the most consistent, and the gap between open-label success at 70% and placebo-controlled success at 22% is the kind of spread that tells you most of the promise lives in the trial design. The ingredient carries little of it. So "tried everything" usually means you tried the things that were never going to clear the bar. What has never been in a trial at all is the stuff that moves desire in most people anyway: sleep, the load you carry, and the relationship itself. Those are the levers worth pulling before you call the search over. We cover libido after stopping antidepressants, and what HSDD actually means covers the term itself.

The everyday levers, and where a botanical fits

Start with who this section is not for. Blood-pressure medication, heart conditions, kidney and lung problems are exactly what NUUD's own label warns about: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For many readers of this article, that sentence is the answer. Talk to your prescriber first and bring the label.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

• Sleep, in quantity and quality, since fatigue and broken sleep feed a flat drive. Sleep, libido and testosterone covers that.
• Movement you can sustain. Exercise and libido covers the wider picture.
• Treating the depression or the anxiety as the first lever, since the illness carries part of the drop and it is the one thing your prescriber can adjust directly.
• Time and safety, with a partner or on your own, with nothing expected at the end.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general. It does nothing for depression, anxiety, PMDD, or the side effects of Zoloft or any antidepressant, and it has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, with onset in roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your prescriber decides the rest. If your prescriber has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Your prescriber wrote that prescription knowing where sertraline sits. In the 2009 meta-analysis that ranked ten antidepressants by how much they lowered sexual function, sertraline came first, and the overall range across those ten ran from 25.8% to 80.3%. In the large Spanish study, 62.9% of the 159 people on sertraline reported a change when asked directly. That is a known property of the medicine, planned for, weighed against the benefit. It is not a sign that something is broken in you. The depression, the anxiety, and the life you are carrying all flatten wanting on their own, and they sit underneath the drug effect the whole time. If you are taking it for PMDD, the picture is similar: a Cochrane review of premenstrual syndrome and PMDD found a sexual side effect at an odds ratio of 2.32, 95% CI 1.57 to 3.42, versus placebo. None of that points at a flaw in you. You want to want it again, and you just want to feel normal again. Both are reasonable things to ask for, and both start with the conversation above.

Keep reading

• SSRIs and the libido drop: what helps
• Does Lexapro affect sex drive?
• Does Wellbutrin affect sex drive?
• Antidepressants and low libido
• Low libido in women
• Why is my libido so low?

Frequently asked questions

Does Zoloft lower sex drive?
Yes, and it sits at the top of the rankings. In the 2009 meta-analysis, sertraline ranked first among ten antidepressants for lowering sexual function, with the overall range across those ten running from 25.8% to 80.3%, a span that covers all ten drugs and not sertraline alone. In the 1,022-person Spanish study, 62.9% of the 159 people on sertraline reported a change when asked directly. That study was open-label with direct questioning, so the figure is a strong point estimate and no precise measurement.

Does Zoloft affect sex drive in women differently than men?
The one head-to-head number we have splits by sex. In the 1,022-person Spanish study, 62.4% of men and 56.9% of women reported a change, with women reporting higher severity, and about 40% had low tolerance. The study was open-label with direct questioning, so the rates are upper-bound figures, and no exact incidence. No study in this set isolated sertraline alone by sex, so treat the gap as directional.

Will my sex drive come back if I stop Zoloft?
Nobody can say for one person, and no study in these sources measured desire after stopping sertraline, so we will say so plainly. While staying on an SSRI, the side effect does not resolve in most people, and neither dose nor time on the drug predicts it. There is also no randomized trial of drug holidays. Before any change, talk to your prescriber, and read our guide to libido after stopping antidepressants.

Is Zoloft worse than Lexapro or Prozac for sex drive?
Sertraline tops the 2009 ranking, with fluoxetine fifth and escitalopram ninth. A broader network meta-analysis of 63 studies covering more than 26,000 people found most drugs compared at similar risk, with wide credible intervals, bupropion significantly lower and escitalopram and paroxetine significantly higher. The honest answer: sertraline leads the ranking, but most drugs compare similar, and the intervals are wide enough that no single drug clearly loses.

Can I take a botanical supplement with Zoloft?
Ask your prescriber first, and bring the label. The caution reads: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. NUUD does nothing for depression, anxiety, PMDD, or medication side effects, and no interaction studies exist for this formula, so the decision is yours and your prescriber's, made with that label in front of you.

References

1. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of clinical psychopharmacology. 2009;29(3):259-66. https://pubmed.ncbi.nlm.nih.gov/19440080/
2. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of clinical psychiatry. 2001;62 Suppl 3:10-21. https://pubmed.ncbi.nlm.nih.gov/11229449/
3. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. The Journal of clinical psychiatry. 2002;63(4):357-66. https://pubmed.ncbi.nlm.nih.gov/12000211/
4. Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug safety. 2014;37(1):19-31. https://pubmed.ncbi.nlm.nih.gov/24338044/
5. Kearns B, Cooper K, Orr M, Essat M, Hamilton J, Cantrell A. The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Neuropsychiatric disease and treatment. 2022;18:1133-1143. https://pubmed.ncbi.nlm.nih.gov/35698594/
6. Khazaie H, Rezaie L, Rezaei Payam N, Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial. General hospital psychiatry. 2015;37(1):40-5. https://pubmed.ncbi.nlm.nih.gov/25467077/
7. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947-55. https://pubmed.ncbi.nlm.nih.gov/11743835/
8. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry. 2006;67(6):874-81. https://pubmed.ncbi.nlm.nih.gov/16848646/
9. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstetrics and gynecology. 2007;109(4):823-30. https://pubmed.ncbi.nlm.nih.gov/17400842/
10. Jespersen C, Lauritsen MP, Frokjaer VG, Schroll JB. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. The Cochrane database of systematic reviews. 2024;8(8):CD001396. https://pubmed.ncbi.nlm.nih.gov/39140320/
11. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. The Cochrane database of systematic reviews. 2013;2013(5):CD003382. https://pubmed.ncbi.nlm.nih.gov/23728643/
12. Luft MJ, Dobson ET, Levine A, Croarkin PE, Strawn JR. Pharmacologic interventions for antidepressant-induced sexual dysfunction: a systematic review and network meta-analysis of trials using the Arizona sexual experience scale. CNS spectrums. 2021;:1-10. https://pubmed.ncbi.nlm.nih.gov/33843553/
13. de Aquino ACQ, Sarmento ACA, Teixeira RLA, Batista TN, de Freitas CL, Mármol JMP, et al. Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo, Brazil). 2025;80:100602. https://pubmed.ncbi.nlm.nih.gov/39985829/
14. Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS spectrums. 2020;25(1):50-63. https://pubmed.ncbi.nlm.nih.gov/31010445/
15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. The journal of sexual medicine. 2015;12(10):2036-48. https://pubmed.ncbi.nlm.nih.gov/26331383/
16. Katz AJ, Dusetzina SB, Farley JF, Ellis AR, Gaynes BN, Castillo WC, et al. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy. 2012;32(3):234-43. https://pubmed.ncbi.nlm.nih.gov/22392456/
17. Chan ACY. Comparative Real-World Safety Profiles of Six Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis. Cureus. 2025;17(12):e98677. https://pubmed.ncbi.nlm.nih.gov/41510438/
18. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. The Journal of clinical psychiatry. 2005;66(1):100-6. https://pubmed.ncbi.nlm.nih.gov/15669895/

This article is for general education and is not medical advice. Depression, anxiety and PMDD are medical conditions that only a licensed clinician can diagnose and manage, and Zoloft (sertraline) is a prescription medicine. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing depression, anxiety, PMDD, the side effects of any medication, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.